BEAM: Two patients at 40 mg reached 15 hours fasting and stopped starch supplementation

What happened

BEAM-301 data showed glucose-restoration signals, with 2 of 3 patients at 40 mg reaching the 15-hour fasting maximum and stopping starch supplementation. The BEAM-304 platform showed consistent preclinical correction across three PKU variants.

Confirmed

Global impact / market context

If these early signals hold in larger trials, a treatment that restores glucose control and removes starch supplements could reduce daily disease management for patients, which would strengthen Beam Therapeutics' pipeline value and support future revenue prospects.

Analyst inference

The results are very early, coming from a few patients in one study plus preclinical work, so they do not yet prove the therapy works at scale. Investors should treat the news as an early signal rather than confirmed clinical benefit.

Analyst inference

What to watch

1. Two of three patients at 40 mg reached the 15-hour fasting maximum and stopped starch supplementation, a small sample that needs confirmation in more patients. Confirmed
2. Watch whether Beam announces larger trials testing the 40 mg dose, since broader patient numbers would show whether the glucose-restoration signal holds consistently. Proposed
3. Track follow-up BEAM-304 preclinical results across the three PKU variants, because consistent correction there would support moving the platform toward human testing. Analyst inference

Evidence

• Original source link unavailable